DelveInsight’s, “Peanut Allergy Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the Peanut Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peanut Allergy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Peanut Allergy Treatment Landscape @ https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight

Key Takeaways from the Peanut Allergy Pipeline Report

• On June 26, 2026- National Institute of Allergy and Infectious Diseases (NIAID) conducted a study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for the treatment of peanut allergy. Study participation is divided into 3 periods: (i) a monotherapy period comprised of injections of either Tezepelumab or placebo from week 0 to week 8, (ii) followed by a combination therapy period comprised of 56 weeks during which peanut OIT is built up and maintained, and (iii) a treatment withdrawal period comprised of 12 weeks. This study will enroll 62 peanut-allergic individuals from 12 to 55 years of age who experience dose-limiting symptoms to <=100 mg of peanut protein in a single dose (<= 144 mg cumulative dose) as assessed by DBPCFC.
• On June 25, 2026- Ukko Inc. announced a study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
• On June 18, 2026- DBV Technologies represented a phase 3 study of 6-months duration to assess the safety of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE). The overall maximum study duration for each participant will be approximately 112 weeks: Screening Period of 6-weeks, DBPC Treatment Period of 26-weeks, Open-label Period of 78-weeks and Follow-up Period of 2-weeks.
• On June 12, 2026- Novartis Pharmaceuticals initiated a study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy was measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.
• On June 05, 2026- RAPT Therapeutics Inc. highlighted a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks.
• DelveInsight’s Peanut Allergy Pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies for Peanut Allergy treatment.
• The leading Peanut Allergy Companies such as Allergy Therapeutics, DBV Technologies, Novartis, Aravax, ALK-Abello, Intrommune Therapeutics, LAPIX Therapeutics, and others.
• Promising Peanut Allergy Pipeline Therapies such as Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.

Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Peanut Allergy Clinical Trials Assessment

The Peanut Allergy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Peanut Allergy Pipeline Report also highlights the unmet needs with respect to the Peanut Allergy.

Peanut Allergy Overview

Peanut allergy is one of the most common and severe food allergies, particularly in children, and poses a significant public health concern due to its potential to trigger life-threatening anaphylactic reactions. It occurs when the immune system mistakenly identifies peanut proteins as harmful, leading to an exaggerated immune response upon exposure. Even trace amounts of peanuts can provoke symptoms ranging from mild hives and swelling to severe breathing difficulties and cardiovascular complications. The condition often develops early in life and tends to persist into adulthood, necessitating strict dietary avoidance and emergency preparedness, including the use of epinephrine auto-injectors.

Peanut Allergy Emerging Drugs Profile

• Remibrutinib: Novartis

Remibrutinib (LOU064), an oral, novel, covalent BTK inhibitor, has shown high selectivity and potency for BTK, which is implicated in CSU. It is an oral BTK inhibitor that blocks the BTK cascade and prevents the release of histamine that causes itchy hives (wheals) and swelling. The high selectivity and tolerability of remibrutinib are likely attributable to its ability to bind to an inactive conformation of BTK. Currently, the drug is being investigated in Phase II Stage of clinical investigation for Peanut Allergy.

• VLP Peanut: Allergy Therapeutics

VLP Peanut (Polyvac peanut) vaccine is under development for the prevention of peanut allergy. The vaccine candidate is administered by subcutaneous and intravenous route. It consists of a recombinant peanut allergen coupled with a virus-like particle (VLP) adjuvant. It is developed based on virus-like particles (VLP) technology. VLP Peanut consists of two proteins: a capsid subunit derived from Cucumber mosaic virus engineered with a universal T-cell epitope (CuMVTT ) and a CuMVTT subunit fused with peanut allergen Ara h 2 (CuMVTT -Ara h 2), forming mosaic VLPs. Currently, the drug is being investigated in Phase I Stage of clinical investigation for Peanut Allergy.

• INT301: Intrommune Therapeutics

INT301 is the initial product in development by Intrommune specifically designed to help those who suffer from peanut allergy. The product is intended to significantly raise a patient’s immune threshold through daily use of OMIT toothpaste beyond what has triggered a potentially dangerous allergic reaction via accidental exposure. This additional protection helps relieve the persistent anxiety of peanut allergic individuals toward accidental exposure. Currently, the drug is being investigated in Phase I Stage of clinical investigation for Peanut Allergy.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Peanut Allergy Unmet Needs

The Peanut Allergy Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Peanut Allergy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peanut Allergy Treatment.
• Peanut Allergy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peanut Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peanut Allergy market

Peanut Allergy Companies

Allergy Therapeutics, DBV Technologies, Novartis, Aravax, ALK-Abello, Intrommune Therapeutics, LAPIX Therapeutics and others.

Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Peanut Allergy Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

See the latest progress in drug development and clinical research @ Peanut Allergy Market Drivers and Barriers, and Future Perspectives

Scope of the Peanut Allergy Pipeline Report

• Coverage- Global
• Peanut Allergy Companies- Allergy Therapeutics, DBV Technologies, Novartis, Aravax, ALK-Abello, Intrommune Therapeutics, LAPIX Therapeutics and others.
• Peanut Allergy Pipeline Therapies- Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.
• Peanut Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peanut Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Peanut Allergy Pipeline Analysis Today! @ Peanut Allergy Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Peanut Allergy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peanut Allergy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. DBV712: DBV Technologies
9. Mid Stage Products (Phase II)
10. PVX-108: Aravax Pty Ltd
11. Early Stage Products (Phase I/II)
12. INP20: InnoUp Farma S.L.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Peanut Allergy Key Companies
17. Peanut Allergy Key Products
18. Peanut Allergy- Unmet Needs
19. Peanut Allergy- Market Drivers and Barriers
20. Peanut Allergy- Future Perspectives and Conclusion
21. Peanut Allergy Analyst Views
22. Peanut Allergy Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight